粪菌移植治疗尿路感染
本文综述粪菌移植(FMT)治疗复发性尿路感染(rUTI)的作用。研究检索PubMed与Web of Science截至2025年5月的临床试验、队列研究、病例报告等,发现FMT可减少rUTI发作、降低多重耐药菌负荷并提高肠道菌群多样性,但结局不一,存在供体粪便病原体持续或传播的安全隐患,尚需随机对照试验。
要点
- FMT可能减少rUTI发作,尤其伴肠道菌群失调或MDRO定植者
- 部分既往抗生素预防无效者经FMT获得较长无感染期
- 需警惕供体粪便病原体持续或传播,强调安全与筛查
核心结论
- FMT是管理rUTI有前景的微生物组干预手段,尤其适用于复杂或抗生素耐药病例,但需随机对照试验评估疗效、确定最佳方案并解决安全问题。
研究设计与样本
- 综述,检索PubMed与Web of Science截至2025年5月的同行评议文献,纳入临床试验、队列研究、病例报告、经济分析和专家综述。
主要发现
- 临床研究与病例报告一致报告FMT后UTI频率下降、MDRO负荷降低、肠道菌群多样性增加。
- 既往对抗生素预防无效的患者经FMT获得较长无感染期。
- 微生物组分析常显示尿路病原体丰度下降并向供体样菌群转变。
- 部分患者出现结局不一,或供体粪便中尿路病原体持续存在或传播。
临床怎么用
- FMT可考虑用于复杂或抗生素耐药的rUTI患者,尤其伴肠道菌群失调或MDRO定植者。
- 应用前需重视供体粪便筛查与安全监测,防范病原体传播。
- 将FMT纳入常规UTI诊疗前需建立标准化操作规范。
局限性
- 结局存在差异,部分患者无效或出现病原体持续/传播。
- 缺乏随机对照试验证据,最佳方案尚未确定。
- 需进一步解决安全性与供体筛查问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent urinary tract infections (rUTIs) are a major clinical burden, increasingly complicated by multidrug-resistant organisms (MDROs) and antibiotic overuse. Growing evidence implicates gut microbiota dysbiosis as a key contributor to urinary tract infections (UTI) susceptibility, with the gastrointestinal tract acting as a reservoir for uropathogens. OBJECTIVES: This review examines the emerging role of faecal microbiota transplantation (FMT) as a therapeutic strategy for rUTIs. We synthesize findings from human studies and case reports, evaluate microbiological and clinical outcomes post-FMT, and discuss mechanistic insights, safety concerns, and future research directions. SOURCES: We reviewed peer-reviewed publications up to May 2025 using PubMed and Web of Science. Included sources comprised clinical trials, cohort studies, case reports, economic analyses, and expert reviews concerning FMT and UTIs. CONTENT: FMT has shown promise in reducing rUTI episodes, particularly in patients with underlying gut dysbiosis or MDRO colonization. Clinical studies and case reports consistently report decreased UTI frequency, lower MDRO burden, and increased gut microbiota diversity post-FMT. Patients previously refractory to antibiotic prophylaxis achieved prolonged infection-free periods. Microbiome analyses often reveal reductions in uropathogen abundance and shifts towards donor-like microbial communities. However, outcomes vary, and some patients experience persistence or transmission of uropathogens from donor stool, underscoring safety and screening concerns. IMPLICATIONS: FMT represents a promising microbiome-based intervention for managing rUTIs, particularly in complex or antibiotic-resistant cases. Randomized controlled trials are needed to assess efficacy, define optimal protocols, and address safety concerns. Standardized practices will be essential to integrate FMT into routine UTI care.
引用
- Belvončíková P, Gardlík R. Faecal microbiota transplantation for urinary tract infections. Clin Microbiol Infect. 2025. PMID: 41022353. doi:10.1016/j.cmi.2025.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。